ASND
Ascendis Pharma A/S
$243.37
+0.16%
2026-10-23
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Key Fundamentals
EPS (TTM)
€12.83
ROE
118.8%
Revenue Growth (YoY)
114.7%
Profit Margin
70.8%
Debt/Equity
31.33
Beta
0.43
Market Cap
$14.84B
Avg Volume (10D)
1.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$272.47
60D Low
$219.52
Avg Volume
714K
Latest Close
$243.37
Get breakout alerts for ASND
Sign up for Breakout Scanner to receive daily notifications when ASND triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Ascendis Pharma A/S (ASND) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ASND daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ASND operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.